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Human pituitary tumors are generally benign adenomas causing considerable morbidity
due to excess hormone secretion, hypopituitarism, and other tumor mass effects.
Pituitary tumors are highly heterogeneous and difficult to type, often containing mixed cell
phenotypes. We have used calcium imaging followed by multiple immunocytochemistry
to type growth hormone secreting (GHomas) and non-functioning pituitary adenomas
(NFPAs). Individual cells were typed for stored hormones and calcium responses to classic
hypothalamic releasing hormones (HRHs). We found that GHomas contained growth
hormone cells either lacking responses to HRHs or responding to all four HRHs. However,
most GHoma cells were polyhormonal cells responsive to both thyrotropin-releasing
hormone (TRH) and GH-releasing hormone. NFPAs were also highly heterogeneous.
Some of them contained ACTH cells lacking responses to HRHs or polyhormonal
gonadotropes responsive to LHRH and TRH. However, most NFPAs were made of cells
storing no hormone and responded only to TRH. These results may provide new insights
on the ontogeny of GHomas and NFPAs.
Keywords: pituitary adenomas, GHomas, somatotropinomas, non-functioning pituitary adenomas, hypothalamic
releasing factors, calcium imaging
Introduction
Pituitary adenomas are non-metastasizing neoplasms of adenohypophyseal cells occurring with
an incidence extrapolated from autopsies larger than 20%. In addition, common mutations of
oncogenes and tumor suppressor genes present in non-endocrine neoplasms, such as PKC, RAS,
P53 and RB, are usually absent in pituitary adenomas. Multiple evidence indicate that pitu-
itary tumors are monoclonal in nature (1) suggesting five well-defined types of pituitary ade-
nomas (1, 2). Pituitary tumors are classically typed according to morphometric and secretory
characteristics (3). For example, pituitary tumors secreting growth hormone (GH), called also
GHomas or somatotropinomas, represent about 15% of all pituitary tumors detected (4). They are
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characterized by excess of GH secretion causing acromegaly
in adults and gigantism in children. Other frequent pituitary
tumors are the non-functioning pituitary adenomas (NFPAs) rep-
resenting around 20% of all pituitary adenomas. These mostly
benign adenomas include null cell adenomas, gonadotroph ade-
nomas staining but not releasing gonadotropins, and silent adeno-
mas resembling silent corticogonadotroph adenomas (5). These
patients suffer of tumor mass effects including headache, visual
disturbances, and hypopituitarism and are usually diagnosed as
macroadenomas after magnetic resonance imaging (MRI).
According to the monoclonal hypothesis, cells from
GH-secreting tumors should express functional receptors
for GH-releasing hormone (GHRH) and store and release GH.
However, paradoxical secretion of alternative anterior pituitary
(AP) hormones has been reported in multiple instances of
pituitary adenoma, including GHoma patients responding to
thyrotropin-releasing hormone (TRH) with GH secretion (6–9)
and acromegaly patients producing prolactin (PRL) upon GHRH
administration (10). Paradoxical secretion has been also noticed
in normal pituitary glands, both in vitro and in vivo (11, 12). These
data suggest that pituitary tumors may comprise cells expressing
multiple AP hormones. Consistently, AP cells co-storing thyroid-
stimulating hormone (TSH) and GH or PRL (13) have been
reported. Multihormonal tumor cells producing GH and TSH
have been isolated from patients affected by acromegaly and
hyperthyroidism (14) and cells co-secreting GH and PRL have
been described in pituitary adenomas from acromegalics (15).
Additionally, mRNA for both GH and PRL has been detected in
the tumors of patients with a clinical diagnosis of acromegaly or
gigantism (16).
We have previously shown that a series of human pituitary
adenomas including prolactinomas, pituitary adenomas associ-
ated to multiple endocrine neoplasia type I (MEN I) disease,
pituitary tumors linked to Cushing’s disease, and a few NFPA
contained indeed cells storing more than one AP hormone (mul-
tihormonal cells) and/or showing responses to more than one
hypothalamic releasing hormone (HRH) (multiresponsive cells)
(17). For this end, we used fluorescence imaging of individual
cells loaded with fura2 to record the rises in cytosolic Ca2+
concentration ([Ca2+]cyt) induced by specific HRHs added and
removed sequentially. It is well established that stimulation of each
of the four classic HRH receptors induced a rise in [Ca2+]cyt,
in specific cell subpopulations, thus providing functional evi-
dence of expression of specific HRH receptors in individual
cells. Combination of this approach to multiple immunocy-
tochemistry in the very same cells used for calcium imaging
provides the advantage of characterizing the hormones stored
and the functional HRH receptors expressed at the single-cell
level (17, 18).
However, the number of NFPA studied in our former study was
very too low and no data were obtained from GHomas. Accord-
ingly, we aimed here at characterizing the phenotype of individual
cells fromhumanGHomas and additionalNFPAs according to the
hormones stored and functional (calcium) responses to the four
classic HRHs including TRH, GHRH, corticotrophin-releasing
hormone (CRH), and gonadotropin-releasing hormone. For this
end, we used a combination of multiple immunofluorescence and
calcium imaging applied on the same individual cells reported
previously (17, 18).
Materials and Methods
Materials
Antisera against human AP hormones FSHβ (AFP 891891),
GH (AFPC11981A), LHβ (AFP55951889), PRL (AFP55781789),
TSHβ (AFP55741789), and ACTH (AFP39032082Rb) were gen-
erous gifts from the National Hormone and Pituitary Program
(Torrance, CA, USA) and Dr. A. F. Parlow. Human HRHs
(GHRH, TRH, LHRH, and CRH) were purchased from Sigma
(Madrid, Spain). Fluorescent antibodies were prepared by labeling
withOregonGreen 488, CascadeYellow, orAlexa 350 and purified
over a protein A-Sepharose column (17). Fura-2/AM, Oregon
Green 488-isothiocyanate, Cascade Yellow succinimidyl ester, and
Alexa 350 succinimidyl ester were purchased from Molecular
Probes (Eugene, OR, USA).
Human Pituitary Tumor Cell Culture
All the procedures used here were approved by theValladolidUni-
versity Hospital and the Valladolid University School of Medicine
ethical committees. Selected patients were asked to sign an
informed consent form. Fresh pituitary tumor tissue was obtained
at the time of surgery and quickly carried to the laboratory in
cold minimal essential medium (MEM, Invitrogen, Carlsbad, CA,
USA). Extreme care was taken to ensure that samples used for
cell culture were devoid of any contaminating normal tissue.
Tissue was transferred to fresh MEM medium at room temper-
ature, washed extensively with the same medium and quickly dis-
persed with trypsin (1mg/ml) for 15–30min at 37°C. Dispersed
cells washed twice, plated onto coverslips previously coated with
0.01mg/ml poly--lysine and cultured in Dulbecco’s modified
Eagle’s Medium (DMEM, Invitrogen) supplemented with 10%
fetal bovine serum and antibiotics for at least 2 h for recovery.
Further details have been reported previously (17, 18).
Calcium Imaging
Calcium imaging was carried out as previously reported (18, 19).
Briefly, after a few hours of dispersion to allow recovery from
trypsin digestion, cells were incubated with Fura-2/AM (4µM)
for about 1 h at room temperature (25°C) in standard medium
containing 145mMNaCl, 5mMKCl, 1mMMgCl2, 1mMCaCl2,
10mM Hepes (pH 7.4), and 10mM glucose. Then, attached
cells were washed in the same medium, placed in a thermostat-
ically controlled (37°C) stage of an inverted microscope (Diaphot;
Nikon, Tokyo, Japan), and perfused with prewarmed standard
medium.Cells were epi-illuminated alternately at 340 and 380 nm,
and light emitted above 520 nm was recorded using a Magical
Image Processor (Applied Imaging, Newcastle, UK). Pixel-by-
pixel ratios of consecutive frames were obtained and cytosolic free
calcium concentration ([Ca2+]i) was estimated from these ratios
by comparison with Fura-2/AM standards. Test solutions made of
standard medium containing 10 nMHRHs were perfused for 30 s
at the times indicated. A depolarizing solution containing 150mM
K+ (added in exchange forNa+) was perfused for 10 s at the end of
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the experiment to reveal healthy cells bearing functional voltage-
operated Ca2+ channels. Cells not responding to the high-K+
concentration stimulus (usually <5% of the total) were excluded
from the analysis.
Multiple Sequential Immunocytochemistry
After calcium imaging, the very same studied cells were typed
by the hormone/s they stored using the sequential immunocyto-
chemistry protocol previously reported (17). Briefly, cells on the
microscope’s stage were carefully fixed with 4% paraformaldehyde
(PFA) in PBS without losing the microscopic field. Then, cells
were treated with 0.3% Triton X-100, and washed with PBS in the
same conditions. After a fewminutes, 10% goat serum in PBS was
added. After 5min, cells were incubated with antibodies against
three humanAP hormones (TSH, FSH, and LH) labeledwithOre-
gon Green 488, Cascade Yellow, and Alexa 350, respectively, for
30min. After extensive washing using the perfusion system, flu-
orescence images corresponding to each fluorophore were taken
[Oregon Green (FSH): excitation, 490 nm; emission, >510 nm;
Cascade Yellow (TSH): excitation, 380 nm; emission, >510 nm;
and Alexa 350 (LH): excitation, 340 nm; emission, >450 nm].
This step enables typing cells storing TSH, LH, or FSH as well as
cells co-storing combinations of these hormones. After imaging,
cells were again washed extensively using the perfusion system
and incubated with a second series of antibodies against GH,
PRL, and ACTH labeled with Oregon Green 488 (PRL), Cascade
Yellow (GH), and Alexa 350 (ACTH) for 30min. Then, cells were
washed, and three new fluorescence images were taken with the
same fluorescence settings described above. This new image series
revealed both cells thatwere stained by the first antibody and those
labeled by the second one. Cells stained only by the second series
of antibodies were identified by image subtraction. Finally, nuclei
were stained with Hoechst 33258 (0.5µg/ml, 10min) before a
last image was acquired (excitation, 340 nm; emission,>420 nm).
Further details and controls for this procedure have been reported
previously (17, 18).
Results
Strategy for Typing of Human Pituitary Adenoma
Cells
The most relevant clinical and pathological features of 9 human
pituitary GHomas adenomas and 11 NFPAs used in this study
are summarized in Table 1. Male and female patients were
TABLE 1 | Clinical features of the human pituitary adenomas used.
No. Sex, age Clinical features Size (mm) ICC
1 M, 60 Sexual dysfunction (92 nmol/l IGF-1) 20 GH++
FSH++
LH++
2 M, 51 Acromegaly 35 Unknown
2recid 52
3 W, 45 Acromegaly (98 nmol/l IGF-1, 40 ng/ml GH) 10 GH++
4 M, 51 Acromegaly (83 nmol/l IGF-1, 20 ng/ml GH, 183mg/ml PRL) 15 GH++
PRL++
5 W, 66 Acromegaly (84 nmol/l IGF-1) 5 GH+++
6 W, 65 Acromegaly 30 Unknown
7 M, 28 Acromegaly 20 Unknown
8 W, 52 Acromegaly (84 nmol/l IGF-1) Invasive GH++
PRL+
LH+
9 M, 45 Non-functioning, visual defects, headache, low TSH, LH, and testosterone 35 ACTH++
10 W, 55 Non-functioning, visual defects, low TSH, and LH 40 FSH+++
11 M, 76 Non-functioning, hypopituitarism (8 years) 30 ACTH+
12 W, 37 Non-functioning, hyperprolactinemia (40 ng/ml PRL), amenorrhea, galactorrhea 12 Negative
13 M, 59 Non-functioning, hypopituitarism 23 FSH+
14 W, 53 Non-functioning, visual defects 29 ACTH+
15 M, 39 Non-functioning, visual defects, headache, cortisol 8 a.m. 24 g/dl, ACTH a.m. 63 pg/ml 30 ACTH++
16 W, 75 Non-functioning, low thyroid hormones 35 Unknown
17 W, 57 Non-functioning, visual defects, low GH, and LH, ACTH a.m. 80 pg/ml 40 Unknown
18 M, 67 Non-functioning, visual defects, hypopituitarism 30 Unknown
19 W, 60 Non-functioning, visual defects, hypopituitarism 30 LH++
FSH+
PRL+
W, woman; M, man; ICC, Immunocytochemistry.
The size of the tumor represents the maximum diameter of the tumor. All the patients with nonfunctioning pituitary adenoma were diagnosed on the basis of visual defects and magnetic
resonance imaging.
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45–66 years old and selected because they were clinically diag-
nosed of either acromegaly or NFPA before being subjected to
neurosurgery for adenoma ablation. In the case of GHomas, three
adenomas out of five that had been studied by immunohistochem-
istry at the pathology department stained positive for GH and
another hormone, supporting the status of “paradoxically secret-
ing tumors.” Paradoxical secretion was suspected, for instance,
in patient #4, who presented increased serum levels of PRL.
Experiments were conducted to study functional responses to the
four classic HRHs andmultiple sequential immunocytochemistry
(MSPI) for testing single or multiple AP hormone content in the
same, individual cells.
Figure 1 summarizes the strategy followed for the phenotypic
characterization of pituitary adenoma cells, which was established
first in mouse AP cells (18) and then in other human pituitary
tumors (17). Freshly dispersed pituitary tumor cells were cultured
for a few hours and then loaded with fura-2/AM and subjected
to calcium imaging to monitor Ca2+ responses induced by the
four classic HRHs perfused sequentially (CRH, LHRH, TRH, and
GHRH) (Figures 1A–C). Increases in [Ca2+]i in responsive cells
reflects most likely expression of specific, functional HRH recep-
tors (20–24) (Figure 1A). Responsive cells were considered those
cells showing an increase in [Ca2+]cyt larger than 50 nM either
to only a particular HRH (monoresponsive cells, Figure 1B) or
to more than one HRH (multiresponsive cells, Figure 1C). At the
end of the imaging experiment, cells in the samemicroscopic field
were fixed and subjected to multiple, sequential immunocyto-
chemistry (Figures 1D–F) against the five AP hormones to reveal
content of either single or multiple AP hormones in the same
cells. Based on this analysis, cells were typed as silent, monohor-
monal, and multihormonal depending on whether cells stored no
apparent hormone, a single hormone, and several AP hormones,
respectively. For instance, cells from the same tumor could stain
positively for GH only of for both GH and TSH (Figure 1F).
Characterization of Human GHomas
We have used the above strategy to characterize in the first place
cells derived from nine humanGHomas.Most GHomas displayed
distinct phenotypic characteristics, often even among cells from
the same tumor. According to hormone storage and calcium
responses to the four HRHs, GHomas studied here have been
pooled into three different groups according to the results: Type I,
non-responsive GHomas; Type II, multiresponsive GHomas, and
Type III, TRH and GHRH-responsive GHomas.
Type I (non-responsive GHomas, tumors #1, #2, and #3)
includes tumors in which cells lacked generally responses to any
HRH or responses were observed only in a minor fraction of
cells. In fact, <10% of cells from these tumors responded to CRH,
LHRH, TRH, andGHRH, with little or no intra-tumor differences
(Figure 2A). The sequential immunocytochemical characteriza-
tion in the same cells revealed some heterogeneity in terms of
hormone content. Whereas tumors #2 and #3 contained mostly
GH cells and much less frequently PRL, tumor #1 cells stored no
hormone, although a minor fraction of cells stored FSH, PRL, and
GH (Figure 2A).
Type II, multiresponsive GHomas included two tumors only,
tumor recurrence #2rec and tumor #4. In striking contrast with
FIGURE 1 | Strategy for typing of human pituitary adenoma cells.
Pituitary tumor cells were loaded with fura-2 and subjected to Ca2+ imaging
before sequential immunocytochemistry against the six AP hormones.
(A) Fura2 image shows calcium levels, coded in pseudocolor (0–800 nM,
scale at left) during stimulation with 10 nM GHRH. (B,C) Typical [Ca2+]i
recordings for two individual cells during sequential perfusion with the four
HRHs (20 nM) and high-K+ medium. Cells with [Ca2+]i responses larger than
50 nM were considered responsive. Cells lacking responses to high-K+ were
excluded from analysis. (D–F) Multiple immunocytochemistry images of the
same calcium field. Cells storing GH (GH+) are shown in red (D), cells storing
TSH (TSH+) are shown in yellow (E) and merge image (F) shows two
monohormonal GH  cells (in red) and two multihormonal GH+/TSH+ cells
(in yellow). Data are representative of 547 cells studied in 21 independent
experiments.
type I GHomas, nearly all individual cells in these tumors
responded to all four HRHs (Figure 2B). Although there are no
immunocytochemical results for tumor #4, the patient exhibited
an excessive secretion of both GH and PRL. Interestingly, the phe-
notype of the tumor #2rec differed markedly from the adenoma
obtained 1 year earlier from the same patient (tumor #2). Most
cells stored indeed GH (93%) as did cells from the primary tumor
mass (81%). However, cells from the relapsing tumor (tumor
#2rec) responded to HRHs much more extensively that did their
primary counterparts, with more than 90% of cells responding to
all tested HRHs. Therefore, the relapsing tumor studied showed a
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FIGURE 2 | Phenotypic characterization of non-responsive and
multiresponsive GHomas. (A) The analyses of the three non-responsive
tumors and their average (up graphic on the left) are shown. The percentage
of cells responding to each HRH (with a calcium rise larger than 50 nM) are
shown (meanSEM). The white bar at right shows the percentage of
multiresponsive cells (those showing responses to >1 HRH). The hormonal
content of the cells is given in upper right corner of each panel. Data derived
from 67 cells (2 experiments, tumor #1), 31 cells (one experiment, tumor #2),
and 198 cells (4 experiments, tumor #3). Average data derived from 296 cells
studied in 7 independent experiments. (B) Phenotypic characterization
multiresponsive GHomas. Data from one tumor and one recurrence (Tumor
#2rec and #4) are shown. Data derived from 93 cells (two experiments, #2)
and 25 cells (two experiments, tumor #4). Clinical and pathological data of
these tumors are summarized in Table 1.
marked phenotypic contrast with the original adenoma from the
same patient obtained 1 year earlier (Figure 2A).
Type III, TRH and GHRH-responsive GHomas included most
(five out of nine) GH-secreting adenomas analyzed in this study.
These GHomas responded to both TRH andGHRH showing little
or no response to other HRHs (Figure 3). Tumors #5 and #6
respondedmore prominently toGHRH (~60%of the cells) than to
TRH (~30–40%of the cells) but tumors #7 and #8 respondedmore
frequently to TRH (with 50–60%) than to GHRH. This group
of tumors is the most heterogeneous one in terms of hormone
FIGURE 3 | Phenotypic characterization of TRH and GHRH-responsive
GHomas. Results from five individual tumors (#5 to #8) and the average of all
five studied are shown. Data derived from 32 cells (two experiments, tumor
#5), 23 cells (two experiments, tumor #6), 31 cells (four experiments, tumor
#7), and 11 cells (two experiments, tumor #8). Average data are
representative of 97 cells studied in 10 independent experiments. Other
details as in Figure 2.
content including tumors storing multiple AP hormones. Tumor
#8 constitutes a clear example that may account for paradoxical
secretion. This tumor is made of cells responding most frequently
to TRH (>70%) but all cells store GH (100%). Immunofluores-
cence was not performed on cultured cells from tumor #7 owing
to technical problems.
Characterization of Human Non-Functioning
Pituitary Adenomas
We have characterized also individual cells derived from 11
human NFPAs. There was a large degree of functional differences
among the NFPAs studied. According to hormone storage and
responses to the HRHs, we have pooled also the NFPAs studied
here in three different groups with distinct phenotypic char-
acteristics: Type I, non-functioning ACTHomas; Type II, non-
functioning gonadotropinomas, and Type III, non-functioning,
null cell adenomas.
Type I, non-functioning ACTHomas includes only two tumors
(Tumors #9 and #10). Most cells in these two adenomas stored
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ACTH. In addition, cells were either partially (#9) or barely
(#10) sensitive to CRH. Storage of other hormones or sensitiv-
ity to additional HRH receptors was not observed (Figure 4A).
Type II, non-functioning gonadotropinomas (Tumors #11 to #14)
includes four tumors. Most cells in this group showed Ca2+
responses to TRH and LHRH, and less frequently to GHRH.
Responses to CRH were not observed (Figure 4B, Tumor #14
data not shown). Hormone content was variable among adeno-
mas but the most frequent stored hormones were gonadotropins.
FIGURE 4 | Phenotypic characterization of non-functioning pituitary
adenomas (NFPAs) with ACTH immunopositivity. (A) Analyses of two
NFPA are shown. Percents of cells responding to each HRH with a calcium
rise larger than 50 nM are shown. The white bar at right shows the
percentage of multiresponsive cells (those showing responses to >1 HRH).
Data derived from 24 cells (2 experiments, tumor #9) and 188 cells (2
experiment, tumor #10). (B) Data from four tumors (#11, #12, and #13) and
average are shown. Tumor #14 was made of cells responding (50%) to LHRH
but not to any other HRH. About 25% of cells in this tumor stored either FSH
or LH (not shown). Data derived from 139 cells (1 experiment, tumor #11), 38
cells (2 experiments, tumor #12), 50 cells (1 experiment, tumor #13), and 32
cells (2 experiments tumor #14). Average data are representative of 259 cells
studied in 4 independent experiments. Other details as in Figure 2.
Interestingly, gonadotropins were co-stored with additional AP
hormones including TSH, PRL, GH, and even ACTH. The overall
fraction of multiresponsive cells was as high as 70% of the cells.
Finally, type III, non-functioning null cell adenomas included the
most abundant group (5 out of 11) of NFPAs tested here. These
adenomas showed a very homogeneous phenotype strikingly dif-
ferent from the previous ones. In the five tumors studied (#15
to #19), all the cells showed strong responses to TRH but not to
any other HRH. Regarding hormone storage, all adenomas stored
apparently no hormone except one that stored mostly TSH and
FSH with a lower fraction of cells storing GH (Figure 5).
Discussion
The pituitary gland is considered the master gland in charge of
the endocrine system. Input from the hypothalamus in the form
FIGURE 5 | Phenotypic characterization of non-functioning, null cell
adenomas. Results from five individual tumors (#15 to #19) and the average
of all five studied are shown. Data derived from 54 cells (1 experiment, tumor
#15), 19 cells (1 experiment, tumor #16), 22 cells (2 experiments, tumor #17),
27 cells (2 experiments, tumor #18), and 96 cells (2 experiments, tumor #19).
Average data are representative of 218 cells studied in 8 independent
experiments. Other details as in Figure 2.
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of hypothalamic releasing (and inhibiting) factors controls the
release of specific AP hormones. AP hormones, in turn, modulate
the activity of downstream peripheral glands and tissues that feed-
back at both hypothalamic and pituitary levels. Although pituitary
tumors are generally benign and do not formmetastasis, they have
usually a strong impact on patient’s health due to chronic hor-
mone imbalances and/or tumor mass effects. Pituitary tumors are
typically characterized by its large heterogeneity. This is expected
to some extent since the AP is made of five different cell types
characterized by storage of different AP hormones and sensitivity
to different hypothalamic releasing and inhibiting factors. How-
ever, classification of pituitary tumors is highly controversial. To
improve tumor typing and gain insights on pituitary adenoma
ontogeny, we have characterized hundreds of individual cells from
a series of twenty human pituitary tumors classified clinically as
GHomas and NFPAs, two categories that comprise nearly 40% of
all pituitary tumors. The single-cell phenotypes of other frequent
pituitary adenomas including prolactinomas, adenomas related
to MEN-1 and Cushing, and a few NFPAs has been reported
previously (17).
We found that most GHomas were made of polyhormonal
cells storing GH and showing calcium responses to both TRH
and GHRH (type III GHomas). Other GHomas stored only
GH but responded to all four HRH (type II GHomas) or
were polyhormonal cells lacking responses to any HRH (type I
GHomas). The presence of multifunctional cells (multiresponsive
and/or polyhormonal cells) in human GHomas may explain, in
a simple way, the occurrence of paradoxical secretion, which
has been frequently reported in pituitary tumors (6–13). Con-
sistently, the most common phenotype of GHomas made of
polyhormonal GH cells and showing responses to both TRH
and GHRH may explain paradoxical secretion of GH induced
by several HRHs, most notably TRH. In addition, it may
also explain paradoxical secretion of other AP hormones by
GHomas. No information is available on single-cell pheno-
types in the human, normal AP. Several attempts have been
carried out in samples from organ donors but cell cultures
have failed so far in our hands. However, normal GH cells
from mice are mostly monohormonal cells responding only to
GHRH (18, 25) and the multifunctional phenotype seem to show
up only in demanding physiological situations, a process that
has been related to pituitary plasticity. Accordingly, the abun-
dance of multifunctional phenotypes in human GHomas sug-
gests that adenomas may arise as a consequence of dysfunctional
pituitary plasticity as suggested previously for other pituitary
adenomas (17).
Regarding NFPAS, we found that a large fraction of NFPAs
studied were made of cells holding a very particular pheno-
type: These cells are rather homogenous, store no detectable
hormone (null cells) and responded only to TRH (type III non-
functioning adenomas). Other NFPAs contained polyhormonal
gonadotropes responding to LHRH and TRH (type II non-
functioning adenomas) or monohormonal corticotropes lack-
ing responses to HRHs (type I non-functioning adenomas).
These results are consistent with a previous report showing that
a fraction of NFPA patients show abnormal LH secretion in
response to TRH (26). Accordingly, our type III and type II
NFPAs may well correspond to silent gonadotrope adenomas
expressing TRH receptors and differing simply in the level
of expression of gonadotropins and LHRH receptors. We had
previously reported a similar analysis in a small number of
NFPAs (17). One of these previously reported adenomas was
made of cells storing both GH and PRL reflecting probably a
silent somatoprolactinoma. The other two previously reported
adenomas were made of cells storing no hormone or mostly
ACTH and showing responses to CRH and TRH and to a lesser
extent to GHRH suggesting a corticotrope ontogeny. Accordingly,
the two previously reported NFPAs resemble the type 1 NFPA
reported here.
Hypothalamic releasing hormones are considered more than
simple secretagogues as they are also able to promote proliferation
of target cells. For example, it has been reported that excessive
secretion of GHRH or overexpression of GHRH receptors may
result in deregulated proliferation of somatotrophs, leading to
hyperplasia, and neoplastic transformation (27). Interestingly, a
large fraction of GHomas and most NFPAs studied responded
largely to TRH either alone or in combination with other
HRHs. If confirmed, these results suggest that TRH antago-
nists could be considered for the treatment of a large fraction
of NFPAs. This could be particularly interesting for type III
NFPAs accounting for about 50% of all NFPAs studied here as
they are responsive only to TRH but not to any other HRHS.
According to our results, this possible treatment could be less
effective for type II NFPAs as they are responsive also to LHRH
and GHRH. No effect of TRH antagonists is expected in type
I NFPAs as they lack calcium responses to TRH. However,
in this particular case, a possible effect of CRH antagonists is
expected as cells from these tumors respond to CRH but not to
any other HRH. Further research is required to confirm these
results and to validate TRH and CRH receptors as targets for
NFPAS.
Finally, it has been previously suggested that cell phenotypes
within the normal AP are not static (25, 28). Instead, they are
moving targets that may undergo dramatic changes in demanding
physiological situations such as maturation, puberty, and senes-
cence (29). It is worth noting that even a short period of stressmay
lead to significant changes in AP cell composition, particularly in
females (30). One interesting possibility is that this plasticity, a
particular characteristic of AP cells, may remain in the tumor and
be activated by extrinsic factors, thus providing an explanation for
changes in cell phenotypes in tumor recurrences. This plasticity
may also contribute to explain phenotypic differences among cells
within the same tumor. Further research is required to understand
phenotypic heterogeneity and plasticity in the AP and pituitary
adenomas.
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